Renal denervation for resistant hypertension

Coppolino, Giuseppe; Rivoli, Laura; Bolignano, Davide

doi:10.1002/14651858.cd011499

Cochrane Database of Systematic Reviews 2015

DOI: 10.1002/14651858.cd011499

|View full text |Cite

Renal denervation for resistant hypertension

Giuseppe Coppolino¹,

Laura Rivoli²,

Davide Bolignano³

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2017

2022

Publication Types

Select...

Article3

Relationship

Self Cite0

Independent3

Authors

Journals

Cited by 3 publications

(1 citation statement)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The evidence-based observer is likely to have reached the same conclusions as those recently reported in a Cochrane review of renal denervation: 1) based on low-quality evidence, renal denervation has no effect on major cardiovascular events or renal function; 2) moderatequality evidence shows no effect on BP; and 3) based on lowquality evidence, renal denervation caused an increase in bradycardia episodes. 6 Nevertheless, much was learned from the early trials, and new trials are underway with better devices and study designs to address some of the challenges in patient selection, adherence monitoring, and BP measurement.…”

mentioning

confidence: 99%

Controlling Hypertension: We Have the Tools—We Just Need to Use Them

Hyman

Pavlik

2017

J GEN INTERN MED

View full text Add to dashboard Cite

mentioning

confidence: 99%

Controlling Hypertension: We Have the Tools—We Just Need to Use Them

Hyman

Pavlik

2017

J GEN INTERN MED

View full text Add to dashboard Cite

Renal artery denervation: unsolved questions about mechanisms of changes of systemic hemodynamics

Azovtsev

Evlakhov

2022

Medical academic journal

View full text Add to dashboard Cite

In the review we discussed the clinical and physiological aspects of the use of renal artery denervation as an interventional method of treatment of refractory essential arterial hypertension. The application of radiofrequency denervation may be considered as an additional treatment to drug therapy in patients with arterial hypertension. At the same time, the main emphasis in the performed experimental and clinical studies was made on the assessment of changes in blood pressure, cardiac output and the calculated index of total peripheral resistance. However, there is no satisfactory data in the literature about changes of the venous return, as well as superior and inferior venae cavae flows. To assess the effectiveness of renal artery denervation on arterial and venous vessels resistance shifts, it is necessary to carry out experimental studies with perfusion of isolated organs in the conditions of modeling arterial hypertension in animals. The question of the extent to which denervation of the renal arteries leads to shifts in the reactions of organ venous vessels in response to pressor reflex stimuli also requires further studies on experimental models. There are practically no data in the literature on the degree of influence of renal artery denervation on orthostatic tolerance. To understand the mechanisms of changes in systemic hemodynamics in response to denervation of the renal arteries, it is also necessary to perform further research on the mechanisms of shifts in the capacitive and resistive functions of the pulmonary circulation with an assessment of pulmonary microcirculation.

show abstract

Update on heart failure management and future directions

Choi

Park

Youn

2019

Korean J Intern Med

View full text Add to dashboard Cite

Heart failure (HF) is an important cardiovascular disease because of its increasing prevalence, significant morbidity, high mortality, and rapidly expanding health care cost. The number of HF patients is increasing worldwide, and Korea is no exception. There have been marked advances in definition, diagnostic modalities, and treatment of HF over the past four decades. There is continuing effort to improve risk stratification of HF using biomarkers, imaging and genetic testing. Newly developed medications and devices for HF have been widely adopted in clinical practice. Furthermore, definitive treatment for end-stage heart failure including left ventricular assist device and heart transplantation are rapidly evolving as well. This review summarizes the current state-of-the-art management for HF and the emerging diagnostic and therapeutic modalities to improve the outcome of HF patients.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Renal denervation for resistant hypertension

Cited by 3 publications

References 10 publications

Controlling Hypertension: We Have the Tools—We Just Need to Use Them

Controlling Hypertension: We Have the Tools—We Just Need to Use Them

Renal artery denervation: unsolved questions about mechanisms of changes of systemic hemodynamics

Update on heart failure management and future directions

Contact Info

Product

Resources

About